Kura Oncology, Inc. (KURA)
| Market Cap | 802.08M +61.7% |
| Revenue (ttm) | 71.64M +5.4% |
| Net Income | -294.57M |
| EPS | -3.35 |
| Shares Out | 88.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,101,931 |
| Open | 10.17 |
| Previous Close | 10.20 |
| Day's Range | 9.03 - 10.17 |
| 52-Week Range | 5.45 - 12.49 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 31.17 (+244.99%) |
| Earnings Date | May 12, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price target is $31.17, which is an increase of 244.99% from the latest price.
News
Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
KOMZIFTI's launch in relapsed/refractory NPM1-mutant AML is exceeding expectations, with strong clinical data supporting its use as a combinable backbone. High response rates and robust MRD negativity in AML trials, along with promising results in solid tumors, position the pipeline for significant growth.
Kura Oncology Proxy statement: Proxy filing
Kura Oncology filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
Kura Oncology (KURA) reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor, or FTI, darlifarnib in combination with adagrasib in...
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura ma...
Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026
Ziftomenib is showing strong early uptake in relapsed/refractory NPM1 mutant AML, with robust clinical data and broad payer coverage. Darlifarnib is advancing in combination strategies, with new data and strategic updates expected soon.
Kura Oncology reports Q1 EPS (83c), consensus (78c)
Reports Q1 revenue $18.27M, consensus $25.92M. As of March 31, Kura had $580.8M in cash, cash equivalents and short-term investments, compared to $667.2M as of December 31, 2025. The company…
Kura Oncology Earnings Call Transcript: Q1 2026
KOMZIFTI's launch exceeded expectations with $5.8M in Q1 revenue, strong physician adoption, and 40% of patients receiving combination therapy. Phase III programs are ahead of plan, and robust liquidity supports continued growth and multiple upcoming clinical catalysts.
Kura Oncology Earnings release: Q1 2026
Kura Oncology released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Kura Oncology Quarterly report: Q1 2026
Kura Oncology has published its Q1 2026 quarterly earnings report on May 12, 2026.
Kura Oncology Reports First Quarter 2026 Financial Results
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and com...
Kura Oncology Slides: Corporate presentation
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus da...
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
Kura Oncology to Report First Quarter 2026 Financial Results
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
Kura Oncology Transcript: Investor Update
Updated Phase 1 data show darlifarnib plus cabozantinib achieves a 44% objective response rate and 94% disease control in heavily pretreated, cabozantinib-refractory RCC patients, with a favorable safety profile. Expansion into cabozantinib-naive patients and broader solid tumor combinations is underway.
Kura Oncology Press release: Investor Update
Kura Oncology issued a press release on April 17, 2026, disclosing material business information to investors.
Kura Oncology Slides: Investor Update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
Kura Oncology reports results from ongoing FIT-001 clinical trial
Kura Oncology (KURA) announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib in the ongoing FIT-001 clinical trial o...
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy
Kura Oncology initiated with a Buy at Lake Street
Lake Street initiated coverage of Kura Oncology (KURA) with a Buy rating and $23 price target The firm’s price target is based on the market opportunity for the company’s commercial…
Kura Oncology Proxy statement: Proxy filing
Kura Oncology filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.